Palvella Therapeutics

What Palvella Therapeutics does

Palvella Therapeutics is a clinical-stage biopharmaceutical company developing and preparing to commercialize topical therapies for rare genetic skin diseases and vascular malformations that currently have no FDA-approved treatment options. The company is headquartered in Wayne, Pennsylvania, and has been publicly traded on Nasdaq under the ticker PVLA since a December 2024 reverse merger with Pieris Pharmaceuticals, with its stock uplisted to the Nasdaq Global Market in May 2026. Its pipeline addresses an estimated 1 in 10 Americans with rare diseases, focusing on indications where less than 2% of nearly 600 rare dermatologic diseases have an approved therapy.

The company's core asset is the QTORIN™ proprietary topical drug delivery platform, invented in 2017, which enables high-concentration (3.9%) anhydrous topical gels of large molecular weight molecules such as rapamycin while limiting systemic absorption to picogram levels and maintaining room-temperature chemical stability suitable for chronic dosing. The lead product candidate, QTORIN 3.9% rapamycin anhydrous gel, is being developed for microcystic lymphatic malformations (positive Phase 3 SELVA, NDA planned for 2H 2026), cutaneous venous malformations (positive Phase 2 TOIVA), and angiokeratomas (Phase 2 LOTU, FDA Fast Track Designation); a second candidate, QTORIN pitavastatin, is planned to enter Phase 2 in 2H 2026 for porokeratosis. The QTORIN platform is protected by European patents through 2038 and a Yale-licensed U.S. patent through 2043, with the company holding FDA Breakthrough Therapy, Orphan Drug, and Fast Track Designations on the lead indication.

Palvella is pre-revenue with $261.9M in cash, cash equivalents, and short-term investments as of March 31, 2026, following a $230M upsized public offering. The business model is product sales-oriented with a planned U.S. specialty field sales force, specialty pharmacy distribution, market access, and patient services infrastructure being built ahead of a targeted 1H 2027 commercial launch of QTORIN rapamycin for mLM; a licensing/royalty relationship with Ligand Pharmaceuticals also contributes a royalty stream to Ligand's reported $161M 2025 royalty revenue. Commercial leadership has been recruited from Dompé (Oxervate), Krystal Biotech (VYJUVEK), Incyte (OPZELURA), and Arcutis (ZORYVE), with Stifel peak U.S. sales estimated at $1.6B and Stephens projecting over $1B in revenue by 2032.

Name

Palvella Therapeutics

Legal name

Palvella Therapeutics, Inc.

Website

https://palvellatx.com

Company type

Public

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Palvella Therapeutics is a clinical-stage biopharmaceutical company developing the QTORIN™ topical drug delivery platform to deliver high-concentration rapamycin and other therapies for rare genetic skin diseases and vascular malformations with no FDA-approved treatments, targeting a 1H 2027 U.S. launch of QTORIN rapamycin for microcystic lymphatic malformations.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals / Rare Disease Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Rare Cardiovascular & Vascular Disorder Therapies (HLAIAIAH)

akta.pro secondary industries

Pulmonary Hypertension & Rare Pulmonary Disease Therapies (HLAIAIAG), Rare Dermatology Disorder Therapies (HLAIAIAM)

Keywords

• Topical drug delivery
• Rare disease therapeutics
• Rapamycin formulations
• Rare skin diseases
• Dermatology drug development

Headquarters

HQ city

Wayne

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Future product sales (drug commercialization): Clinical-stage biopharmaceutical company; no commercial revenue today. Future revenue anticipated from U.S. launch of QTORIN rapamycin for microcystic lymphatic malformations targeted for first half of 2027, with Stifel estimating peak U.S. sales of $1.6 billion.
2. Licensing royalties (Ligand Pharmaceuticals): Palvella's QTORIN rapamycin program contributes to Ligand Pharmaceuticals' royalty revenue stream (Ligand reported $161 million royalty revenue in Q4 2025 full-year driven by Palvella's program among others), indicating a licensing/royalty arrangement.

Go-to-market motion4 records

Distribution channels3 records

Marketing channels8 records

Core offering

Palvella Therapeutics is developing and commercializing topical therapies for rare genetic skin diseases and vascular malformations with no FDA-approved treatments, using its proprietary QTORIN™ drug delivery platform. The lead product candidate is QTORIN 3.9% rapamycin anhydrous gel, in development for microcystic lymphatic malformations (Phase 3), cutaneous venous malformations (Phase 2), and angiokeratomas (Phase 2), with NDA submission planned for H2 2026 and potential U.S. launch in 1H 2027.

Differentiator

Problem solved

Functional benefit

Products and services

• QTORIN™ Platform The QTORIN™ platform is Palvella's proprietary topical drug delivery technology invented in 2017 and developed over several years of research and investment. It addresses key technical challenges in topical treatment of rare skin diseases — including achieving therapeutic drug concentrations and chemical stability while minimizing systemic absorption — and supports delivery of high-molecular-weight APIs (e.g., 3.9% rapamycin) into the deep epidermis/dermis. It is patented and trademarked, with patent protection extending into 2038 in Europe and 2043 via a Yale-licensed U.S. patent.
• QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) A novel, patented 3.9% rapamycin anhydrous gel — Palvella's lead product candidate — designed to harness rapamycin as a mammalian target of rapamycin (mTOR) inhibitor delivered topically. It is in development for microcystic lymphatic malformations (Phase 3 SELVA study), cutaneous venous malformations (Phase 2 TOIVA study), angiokeratomas (Phase 2 LOTU), and other mTOR-driven serious, functionally debilitating rare skin diseases. The product has received FDA Breakthrough Therapy, Orphan Drug, and Fast Track designations for microcystic lymphatic malformations, with FDA rolling review granted for the NDA in June 2026.
• QTORIN™ Pitavastatin A second pipeline asset in the QTORIN™ portfolio being evaluated for porokeratosis (specifically disseminated superficial actinic porokeratosis, DSAP), a serious genetic skin disease with no FDA-approved therapies. Supported by a systematic review published in Clinical and Experimental Dermatology, Palvella expects to enter Phase 2 development in the second half of 2026 for an estimated more than 50,000 diagnosed patients in the U.S.

Quantifiable outcome

• Phase 3 SELVA met primary endpoint with mean improvement of +2.13 points on mLM-IGA scale (p<0.001)
• +6 more outcomes

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Seven partnerships are on record, tiered core, flagship and minor.

• Yale UniversitycoreOEM/ Whitelabel/ Licensing Partner · 1 June 2026U.S. patent licensed from Yale University covering topical mevalonate pathway inhibition treatment; patent protection extends through 2043. Provides intellectual property foundation for topical therapy development.
• MedPharmcoreStrategic or Co-development Partner · 1 March 2026MedPharm supported Palvella Therapeutics in developing the QTORIN rapamycin topical gel formulation, including complex physicochemical optimization to target skin tissue locally with minimal systemic exposure; partnership recognized upon announcement of positive Phase 3 SELVA topline results in March 2026.
• Pieris PharmaceuticalsflagshipStrategic or Co-development Partner · 1 July 2024Definitive merger agreement announced July 2024; transaction closed December 2024 enabling Palvella to become a Nasdaq-listed company under ticker PVLA. Concurrent $78.9 million private placement funded operations into late 2027. Merger accelerated development of QTORIN rapamycin for rare genetic skin diseases.
• Lymphangiomatosis & Gorham's Disease Alliance (LGDA)coreGTM or Marketing PartnerPatient advocacy partnership with LGDA, an organization ensuring patients with complex lymphatic anomalies (CLAs) are connected to networks of care and have comprehensive support from peer, medical, and scientific communities.
• International Society for the Study of Vascular Anomalies (ISSVA)coreGTM or Marketing PartnerPartner scientific society; Palvella regularly presents research at ISSVA World Congress including late-breaking abstracts on Phase 3 SELVA and Phase 2 TOIVA studies in May 2026.
• Pediatric Dermatology Research Alliance (PeDRA)minorGTM or Marketing PartnerPartner research organization; Palvella presents clinical research including Phase 3 SELVA fit-for-purpose endpoint and QTORIN rapamycin novel topical mTOR inhibitor Phase 3 studies at PeDRA Annual Conferences.
• Ligand PharmaceuticalscoreOEM/ Whitelabel/ Licensing PartnerPalvella's QTORIN rapamycin program contributes to Ligand Pharmaceuticals' royalty revenue stream (Ligand reported $161 million full-year royalty revenue in 2025 driven partly by Palvella's program). Ligand board member Todd Davis also serves on Palvella's Board of Directors; Palvella CFO Matthew Korenberg was former President/COO and CFO of Ligand.

Scale indicators13 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Arcutis Biotherapeutics: Arcutis is a commercial-stage dermatology biopharmaceutical company that developed ZORYVE (roflumilast), a topical PDE4 inhibitor. Highly comparable given Palvella's Chief Innovation Officer David Osborne was co-founder and CTO of Arcutis, and the companies share a topical drug delivery focus on inflammatory skin diseases with similar commercial infrastructure and specialty sales force build-out.
• Krystal Biotech: Krystal Biotech developed and commercialized VYJUVEK, the first FDA-approved topical gene therapy for dystrophic epidermolysis bullosa, a rare skin disease. Directly comparable given the rare dermatology focus, topical administration, specialty distribution model, and the shared leadership connection (Palvella's SVP Market Access McDonough launched VYJUVEK to $389M annual sales at Krystal).
• Dompé farmaceutici: Dompé commercialized Oxervate (cenegermin), the first FDA-approved therapy for neurotrophic keratitis, a rare disease. Highly comparable given CCO Ashley Kline's track record launching Oxervate to $500M+ U.S. sales at Dompé — both companies operate in rare disease specialty pharmaceutical commercialization with similar patient identification and reimbursement challenges.

Broad incumbents

• Incyte Corporation: Incyte developed and commercialized OPZELURA (topical ruxolitinib) for atopic dermatitis and vitiligo, establishing a 170+ rep dermatology sales force. Comparable as a larger incumbent in topical dermatology with overlapping commercial talent pool — Palvella's SVP Sales Kent Taylor and SVP Medical Affairs Patel both came from Incyte's OPZELURA team.
• BioMarin Pharmaceutical: BioMarin is an established rare disease biopharmaceutical company with multiple commercialized products for rare genetic conditions, including rare skin and metabolic disorders. Comparable as a broad incumbent rare disease player; Board Director Elaine Heron also serves on BioMarin's board, signaling shared governance perspective on rare disease commercial strategy.

Others

• Ligand Pharmaceuticals: Ligand is a biopharmaceutical company with a royalty-based business model that includes Palvella's QTORIN rapamycin program. Comparable as a licensing/royalty partner and ecosystem participant; Ligand CEO Todd Davis sits on Palvella's board and former Palvella CFO Korenberg was Ligand's President/COO/CFO.

Emerging players

• Aclaris Therapeutics: Aclaris Therapeutics is a clinical-stage dermatology biopharmaceutical company developing therapies for immuno-inflammatory skin diseases. Comparable as an emerging player in specialty dermatology with similar pipeline development and rare skin disease focus, though at a more mature commercial stage.
• AnaptysBio: AnaptysBio is a clinical-stage biotechnology company developing inflammatory disease therapeutics, including for dermatology indications. Comparable as an emerging player with a focus on inflammatory skin diseases and similar clinical-stage pipeline economics.
• Dermavant Sciences: Dermavant developed VTAMA (tapinarof), a topical aryl hydrocarbon receptor agonist approved for plaque psoriasis. Comparable as a specialty dermatology company with topical therapeutic focus and similar commercial trajectory in the inflammatory skin disease space.
• Menlo Therapeutics (now Trevi Therapeutics): Trevi Therapeutics is developing therapies for serious dermatologic and neurologic conditions including prurigo nodularis. Comparable as an emerging player in rare dermatology with similar specialty commercial focus and rare disease development economics.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/palvella-therapeutics

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Funding overview

Funding rounds10 records

Investors19 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Palvella Therapeutics